KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $51.3 million.

  • Alnylam Pharmaceuticals' Long-Term Investments fell 2518.95% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.3 million, marking a year-over-year decrease of 2518.95%. This contributed to the annual value of $68.6 million for FY2024, which is 3887.75% up from last year.
  • Alnylam Pharmaceuticals' Long-Term Investments amounted to $51.3 million in Q3 2025, which was down 2518.95% from $68.6 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Long-Term Investments' 5-year high stood at $68.6 million during Q4 2024, with a 5-year trough of $40.7 million in Q1 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Long-Term Investments value was $49.4 million (recorded in 2022), while the average stood at $51.3 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Long-Term Investments soared by 6537.92% in 2021, and later crashed by 2518.95% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Long-Term Investments (Quarter) stood at $40.9 million in 2021, then rose by 20.78% to $49.4 million in 2022, then grew by 0.0% to $49.4 million in 2023, then surged by 38.88% to $68.6 million in 2024, then dropped by 25.19% to $51.3 million in 2025.
  • Its Long-Term Investments was $51.3 million in Q3 2025, compared to $68.6 million in Q2 2025 and $68.6 million in Q1 2025.